[go: up one dir, main page]

AR119857A1 - Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak - Google Patents

Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak

Info

Publication number
AR119857A1
AR119857A1 ARP200102424A ARP200102424A AR119857A1 AR 119857 A1 AR119857 A1 AR 119857A1 AR P200102424 A ARP200102424 A AR P200102424A AR P200102424 A ARP200102424 A AR P200102424A AR 119857 A1 AR119857 A1 AR 119857A1
Authority
AR
Argentina
Prior art keywords
iraq
formulations
inhibition
protein
pyrazole compounds
Prior art date
Application number
ARP200102424A
Other languages
English (en)
Inventor
lu Chou
Matt Duan
Ihab Darwish
Simon Shaw
Somasekhar Bhamidipati
Vanessa Taylor
Yan Chen
Dazhong Fan
Zhushou Luo
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of AR119857A1 publication Critical patent/AR119857A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos derivados de pirazol como inhibidores de la proteína IRAK, composiciones que los comprenden y el uso de los mismos para el tratamiento de enfermedades autoinmunitarias. Reivindicación 1: Un compuesto, que tiene una fórmula (1) o una sal, solvato o N-óxido del mismo, en donde: R es alifático, acilo, heterociclilo, éster carboxílico, amida, alquilfosforamidato o alquilfosfato; o R es H y el compuesto es una sal.
ARP200102424A 2019-08-30 2020-08-28 Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak AR119857A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962894547P 2019-08-30 2019-08-30

Publications (1)

Publication Number Publication Date
AR119857A1 true AR119857A1 (es) 2022-01-19

Family

ID=72473975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102424A AR119857A1 (es) 2019-08-30 2020-08-28 Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak

Country Status (21)

Country Link
US (3) US11370787B2 (es)
EP (1) EP4003990A1 (es)
JP (1) JP2022545542A (es)
KR (1) KR20220054626A (es)
CN (2) CN121159524A (es)
AR (1) AR119857A1 (es)
AU (1) AU2020335903A1 (es)
BR (1) BR112022003564A2 (es)
CA (1) CA3152264A1 (es)
CO (1) CO2022002993A2 (es)
CR (1) CR20220085A (es)
DO (1) DOP2022000047A (es)
EC (1) ECSP22014379A (es)
IL (1) IL290882B1 (es)
JO (1) JOP20220050A1 (es)
MX (1) MX2022002292A (es)
PE (1) PE20220970A1 (es)
PH (1) PH12022550466A1 (es)
SA (1) SA522431791B1 (es)
TW (1) TWI870449B (es)
WO (1) WO2021041898A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022003564A2 (pt) * 2019-08-30 2022-05-17 Rigel Pharmaceuticals Inc Composto, composição, composição seca por pulverização, método de preparação de uma composição seca por pulverização e método
WO2022187303A1 (en) * 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
CA3231050A1 (en) * 2021-09-08 2023-03-16 Rigel Pharmaceuticals, Inc. Irak inhibitor for treating cytokine release-related conditions associated with infection by a respiratory virus
JP2025513716A (ja) 2022-03-23 2025-04-30 ライジェル・ファーマシューティカルズ・インコーポレイテッド Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物
CN119950825B (zh) * 2025-03-13 2025-07-22 北京工业大学 基于压电驱动的自适应释药电纺覆膜气管支架的制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
WO2006070202A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
KR101504787B1 (ko) 2007-10-24 2015-03-20 아스테라스 세이야쿠 가부시키가이샤 아졸카복사마이드 화합물 또는 그 염
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
US8987309B2 (en) 2009-04-17 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles
EP2243481A1 (en) 2009-04-24 2010-10-27 PamGene B.V. Irak kinase family as novel drug target for Alzheimer
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
PH12012501864A1 (en) 2010-04-07 2017-07-26 Hoffmann La Roche Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
PT2730564T (pt) 2010-11-19 2018-07-24 Ligand Pharm Inc Aminas heterocíclicas e suas utilizações
EP2561102A1 (en) 2010-12-02 2013-02-27 Katholieke Universiteit Leuven K.U. Leuven R&D Irak-related interventions and diagnosis
LT2655357T (lt) 2010-12-20 2016-10-10 Merck Serono S.A. Indazolilo triazolo dariniai, kaip irak inhibitoriai
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2012108511A1 (ja) 2011-02-09 2012-08-16 日産化学工業株式会社 ピラゾール誘導体および有害生物防除剤
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
AR088061A1 (es) 2011-09-27 2014-05-07 Hoffmann La Roche Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
BR112014017021A8 (pt) 2012-01-10 2017-07-04 Nimbus Iris Inc inibidores de irak e usos dos mesmos
KR102281288B1 (ko) 2012-09-26 2021-07-26 에프. 호프만-라 로슈 아게 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
US9586948B2 (en) 2012-10-08 2017-03-07 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
SG11201506100XA (en) 2013-02-07 2015-09-29 Merck Patent Gmbh Pyridazinone-amides derivatives
DK2953952T3 (en) 2013-02-07 2017-08-28 Merck Patent Gmbh MACROCYCLIC PYRIDAZININE DERIVATIVES
JP6527163B2 (ja) 2014-01-09 2019-06-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリミジンピラゾリル誘導体及びｉｒａｋ阻害剤としてのその使用
CN107108561B (zh) 2014-11-20 2020-08-28 默克专利有限公司 用作irak抑制剂的杂芳基化合物及其用途
HRP20210433T1 (hr) 2015-04-22 2021-04-30 Rigel Pharmaceuticals, Inc. Spojevi pirazola i postupak za dobivanje i upotrebu spojeva
US10370367B2 (en) * 2016-10-26 2019-08-06 Rigel Pharmaceuticals, Inc. IRAK inhibitors and method for making and using
BR112022003564A2 (pt) * 2019-08-30 2022-05-17 Rigel Pharmaceuticals Inc Composto, composição, composição seca por pulverização, método de preparação de uma composição seca por pulverização e método

Also Published As

Publication number Publication date
CN114364674A (zh) 2022-04-15
JP2022545542A (ja) 2022-10-27
AU2020335903A1 (en) 2022-03-24
DOP2022000047A (es) 2022-04-29
CO2022002993A2 (es) 2022-04-19
PH12022550466A1 (en) 2023-03-06
IL290882B1 (en) 2025-11-01
US20230399326A1 (en) 2023-12-14
CN114364674B (zh) 2025-10-03
CA3152264A1 (en) 2021-03-04
EP4003990A1 (en) 2022-06-01
MX2022002292A (es) 2022-06-02
US20210061798A1 (en) 2021-03-04
WO2021041898A1 (en) 2021-03-04
IL290882A (en) 2022-04-01
US12441723B2 (en) 2025-10-14
TWI870449B (zh) 2025-01-21
PE20220970A1 (es) 2022-06-10
CN121159524A (zh) 2025-12-19
US20220306620A1 (en) 2022-09-29
KR20220054626A (ko) 2022-05-03
US11370787B2 (en) 2022-06-28
JOP20220050A1 (ar) 2023-01-30
CR20220085A (es) 2022-04-19
SA522431791B1 (ar) 2025-04-14
ECSP22014379A (es) 2022-05-31
TW202122393A (zh) 2021-06-16
BR112022003564A2 (pt) 2022-05-17

Similar Documents

Publication Publication Date Title
AR119857A1 (es) Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak
BR112021024131A2 (pt) Derivado de anel inibidor de btk, método de preparação para o mesmo e aplicação farmacêutica do mesmo
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
BR112019018648A2 (pt) Inibidores de jak contendo uma amida heterocíclica com 4 membros
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
CL2021000515A1 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
MX2019000451A (es) Compuesto heterociclico utilizado como inhibidor de fgfr.
MX2021011606A (es) Compuestos dirigidos a prmt5.
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
AR116116A1 (es) Proceso para elaborar inhibidores de jak e intermediarios de los mismos
PE20210176A1 (es) Inhibidores de arginasa y sus metodos de uso
CU20210016A7 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CO2023004420A2 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300
CO2020004669A2 (es) Derivados de bencimidazol y sus usos
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
CR20190236A (es) Compuestos terapéuticos y métodos para utilizarlos